{"id":479398,"date":"2021-04-21T07:33:23","date_gmt":"2021-04-21T11:33:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\/"},"modified":"2021-04-21T07:33:23","modified_gmt":"2021-04-21T11:33:23","slug":"neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\/","title":{"rendered":"NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">\n          <em>Mr. Rubin most recently served as Managing Director, Co-Head Life Sciences for <\/em><br \/>\n          <a href=\"https:\/\/www.soleburytrout.com\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n            <em>Solebury Trout<\/em><br \/>\n          <\/a>\n        <\/li>\n<\/ul>\n<p align=\"left\">GAITHERSBURG, Md., April  21, 2021  (GLOBE NEWSWIRE) &#8212; NexImmune, Inc.\u00a0(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Chad Rubin has been appointed to the newly created position of Senior Vice President, Corporate Affairs. Mr. Rubin will be responsible for all corporate communications, along with involvement in investor and capital markets activities. He joins NexImmune with more than 20 years of experience in investor relations, investment banking and capital markets within the biotechnology sector.<\/p>\n<p align=\"left\">\u201cChad is an important addition to our senior leadership team,\u201d said Scott Carmer, Chief Executive Officer of NexImmune. \u201cWe welcome his breadth of experience in the biotech industry, well-established relationships with the financial community and deep understanding of financial communications and capital markets. He served as a valuable strategic consultant to the company for six years as part of the Solebury Trout, and we look forward to his continued contribution as we continue to evolve NexImmune from a private, development-stage company to a public, clinically driven organization advancing cell-mediated immunotherapy drug candidates for the benefit of patients facing a number of difficult-to-treat diseases.\u201d<\/p>\n<p align=\"left\">Mr. Rubin joins NexImmune from Solebury Trout, a leading investor relations, strategic advisory and capital markets advisor in the life sciences sector, where he was a Managing Director. He most recently served as co-head of the Trout team that provides strategic counsel on investor relations and communication strategies, while also serving as an advisor on capital formation transactions for both private and public biotechnology companies. Mr. Rubin also sits on the Board of Trustees for the Histiocytosis Association, an organization addressing the needs of patients and families dealing with histiocytic disorders and leading the search for a cure.<\/p>\n<p align=\"left\">\u201cThis is an exciting time to join NexImmune.\u00a0The Company\u2019s proprietary nanotechnology\u00a0platform has the potential to positively impact patients\u00a0facing\u00a0cancer, autoimmune disorders and infectious diseases.\u00a0I am honored to be able to contribute to the team\u00a0as we advance our first two product candidates in Phase 1\/2 clinical trials,\u201d\u00a0said Mr. Rubin.<\/p>\n<p align=\"left\">\n        <strong>About\u00a0NexImmune<\/strong>\n      <\/p>\n<p align=\"left\">NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body\u2019s own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune\u2019s approach is its proprietary Artificial Immune Modulation (AIM\u2122) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. NexImmune\u2019s precision technology and unique scientific approach offer promise in restoring hope for patients suffering from cancer, autoimmune disorders, and infectious diseases by directing specific immune responses to attack or moderate cells and other infectious agents causing the underlying disease.<\/p>\n<p align=\"left\">NexImmune\u2019s two lead programs, NEXI-001 and NEXI-002, are in Phase 1\/2 clinical trials for the treatment of relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation and multiple myeloma refractory to at least 3 prior lines of therapy, respectively. In these clinical trials, AIM constructed nanoparticles employ natural biology to engage, activate, and expand endogenous T cells in ways that combine the anti-tumor attributes of antigen-specific precision, potency, and long-term persistence with reduced potential for off-target toxicities.<\/p>\n<p align=\"left\">For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LiaNXd9p6FaKx6QUC66ioQ-9aRzOgSVqK5hD9ny46iORRYuQu9O5pOVyaZiPf98Sb-M9f6ODfFu3P2aGt8dJDg==\" rel=\"nofollow noopener\" target=\"_blank\">www.neximmune.com<\/a>.<\/p>\n<p align=\"left\">\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p align=\"left\">This press release may contain \u201cforward-looking\u201d statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NexImmune, Inc. (the \u201cCompany\u201d). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning our results of operations for the year ended December 31, 2020; the sufficiency of the Company\u2019s current cash and cash equivalents to fund its planned operations through the second quarter of 2022; our planned and ongoing clinical studies for the Company\u2019s product candidates, including NEXI-001 and NEXI-002; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior preclinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential\u201d or \u201ccontinue\u201d or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company\u2019s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the \u201cRisk Factors\u201d section of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission (\u201cSEC\u201d) on March 31, 2021, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company\u2019s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.<\/p>\n<p align=\"left\">\n        <strong>Contacts<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Chad Rubin<br \/>NexImmune<br \/>646-378-2947<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lnmYxrhfb0CSsnURQhO_UTXViJisdh-tVVHNSf3Zs5dJwGHSgcUSfJ-tn5dDtfufcr7boNG_k9dhaP0uBwLqx9m_2UbvD7sfaiANmT93BzI=\" rel=\"nofollow noopener\" target=\"_blank\">crubin@neximmune.com<\/a><\/p>\n<p align=\"left\">\n        <strong>Media:<\/strong><br \/>\n        <br \/>Mike Beyer<br \/>Sam Brown Inc.\u00a0Healthcare Communications<br \/>312-961-2502<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nwsfmygnQFfvgO7uvwRftvA89kWJzVsbq-rdGIfObV12VrbLHWjcnIemZlYiINEs1lRc0ZCjX17txYD6k7mamVwPM4Qf313golvJ61-0km4=\" rel=\"nofollow noopener\" target=\"_blank\"><u>mikebeyer@sambrown.com<\/u><\/a><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDY3OCM0MTMwOTAzIzIwODQxOTk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/6ae93b84-8805-4192-a609-92a20d0daf11\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Mr. Rubin most recently served as Managing Director, Co-Head Life Sciences for Solebury Trout GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) &#8212; NexImmune, Inc.\u00a0(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Chad Rubin has been appointed to the newly created position of Senior Vice President, Corporate Affairs. Mr. Rubin will be responsible for all corporate communications, along with involvement in investor and capital markets activities. He joins NexImmune with more than 20 years of experience in investor relations, investment banking and capital markets within the biotechnology sector. \u201cChad is an important addition to our senior leadership team,\u201d said &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-479398","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Mr. Rubin most recently served as Managing Director, Co-Head Life Sciences for Solebury Trout GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) &#8212; NexImmune, Inc.\u00a0(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Chad Rubin has been appointed to the newly created position of Senior Vice President, Corporate Affairs. Mr. Rubin will be responsible for all corporate communications, along with involvement in investor and capital markets activities. He joins NexImmune with more than 20 years of experience in investor relations, investment banking and capital markets within the biotechnology sector. \u201cChad is an important addition to our senior leadership team,\u201d said &hellip; Continue reading &quot;NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-21T11:33:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDY3OCM0MTMwOTAzIzIwODQxOTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs\",\"datePublished\":\"2021-04-21T11:33:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\\\/\"},\"wordCount\":938,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDY3OCM0MTMwOTAzIzIwODQxOTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\\\/\",\"name\":\"NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDY3OCM0MTMwOTAzIzIwODQxOTk=\",\"datePublished\":\"2021-04-21T11:33:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDY3OCM0MTMwOTAzIzIwODQxOTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDY3OCM0MTMwOTAzIzIwODQxOTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\/","og_locale":"en_US","og_type":"article","og_title":"NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs - Market Newsdesk","og_description":"Mr. Rubin most recently served as Managing Director, Co-Head Life Sciences for Solebury Trout GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) &#8212; NexImmune, Inc.\u00a0(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Chad Rubin has been appointed to the newly created position of Senior Vice President, Corporate Affairs. Mr. Rubin will be responsible for all corporate communications, along with involvement in investor and capital markets activities. He joins NexImmune with more than 20 years of experience in investor relations, investment banking and capital markets within the biotechnology sector. \u201cChad is an important addition to our senior leadership team,\u201d said &hellip; Continue reading \"NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-21T11:33:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDY3OCM0MTMwOTAzIzIwODQxOTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs","datePublished":"2021-04-21T11:33:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\/"},"wordCount":938,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDY3OCM0MTMwOTAzIzIwODQxOTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\/","name":"NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDY3OCM0MTMwOTAzIzIwODQxOTk=","datePublished":"2021-04-21T11:33:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDY3OCM0MTMwOTAzIzIwODQxOTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDY3OCM0MTMwOTAzIzIwODQxOTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-appoints-chad-rubin-as-senior-vice-president-corporate-affairs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=479398"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479398\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=479398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=479398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=479398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}